- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Spring 2018
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Patheon Softgels Inc. v. Apotex Inc., 18-0003 (D. Del.) | Jan. 2, 2018 | Vacant Judgeship (2017) | Naproxen Sodium OTC | 9,693,978 9,693,979 |
| Jazz Pharms., Inc. v. Mallinckrodt PLC, 18-0029 (D.N.J.) | Jan. 2, 2018 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 7,668,730 7,765,106 7,765,107 7,895,059 8,457,988 8,589,182 8,731,963 8,772,306 9,050,302 9,486,426 |
| Bayer Healthcare Pharms. Inc. v. Teva Pharms. USA, Inc., 18-0013 (D. Del.) | Jan. 3, 2018 | Vacant Judgeship (2017) | Finacea® (azelaic acid foam) | 7,700,076 8,435,498 8,722,021 8,900,554 9,211,259 9,265,725 |
| Purdue Pharma L.P. v. Amneal Pharms., LLC, 18-0051 (D. Del.) | Jan. 3, 2018 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) | 9,770,416 9,775,808 |
| Purdue Pharma L.P. v. Kashiv Pharma, LLC, 18-0052 (D. Del.) | Jan. 3, 2018 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) | 9,763,933 9,770,416 9,775,808 |
| Takeda Pharm. Co. Ltd. v. Indoco Remedies Ltd., 18-0055 (D.N.J.) | Jan. 3, 2018 | Hon. Stanley R. Chesler | Kazano® (alogliptin benzoate / metformin HCl tablets) | 7,807,689 8,173,663 8,288,539 8,900,638 |
| Eli Lilly and Co. v. Lupin Ltd., 18-0055 (D. Del.) | Jan. 4, 2018 | Vacant Judgeship (2017) | Cialis® (tadalafil tablets) | 6,943,166 |
| Argentum Pharms. LLC v. Merck Patentgesellschaft, IPR2018-00423 (PTAB) | Jan. 5, 2018 | N/A | Viibryd® (vilazodone HCl tablets) | 8,673,921 |
| Adverio Pharma GMBH v. Alembic Pharms. Ltd., 18-0073 (D. Del.) | Jan. 9, 2018 | Hon. Leonard P. Stark | Adempas® (riociguat tablets) | 6,743,798 |
| Mitsubishi Tanabe Pharma Corp. v. Lupin Ltd., 18-0292 (D.N.J.) | Jan. 9, 2018 | Hon. Peter G. Sheridan | Invokana® (canagliflozin tablets) Invokamet® (canagliflozin / metformin HCl tablets) |
7,943,582 8,513,202 |
| Purdue Pharma L.P. v. Ascent Pharms., Inc., 18-0083 (D. Del.) | Jan. 11, 2018 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) | 9,060,976 9,073,933 9,522,919 9,149,533 9,861,582 8,309,060 9,675,610 |
| Celgene Corp. v. Apotex Inc., 18-0461 (D.N.J.) | Jan. 11, 2018 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 6,315,720 6,561,977 6,755,784 8,315,886 8,626,531 7,465,800 7,855,217 7,468,363 8,741,929 |
| Purdue Pharma L.P. v. Ascent Pharms., Inc., 18-0196 (E.D.N.Y.) | Jan. 11, 2018 | Hon. William F. Kuntz, II | OxyContin® (oxycodone HCl extended-release tablets) | 9,060,976 9,073,933 9,522,919 9,149,533 9,861,582 8,309,060 9,675,610 |
| West-ward Pharms. Corp. v. Granules Pharms., Inc., 18-0085 (D. Del.) | Jan. 12, 2018 | Vacant Judgeship (2017) | Mitigare® (colchicine capsules) | 8,927,607 9,399,036 9,555,029 9,675,613 9,789,108 |
| H. Lundbeck A/S v. Apotex Inc., 18-0088 (D. Del.) | Jan. 12, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Apotex Inc., 18-0089 (D. Del.) | Jan. 12, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Lupin Ltd., 18-0090 (D. Del.) | Jan. 12, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Macleods Pharms. Ltd., 18-0091 (D. Del.) | Jan. 12, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Unichem Labs., Ltd., 18-0092 (D. Del.) | Jan. 12, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| Patheon Softgels Inc. v. Ohm Labs. Inc., 18-0486 (D.N.J.) | Jan. 12, 2018 | Hon. Michael A. Shipp | Naproxen Sodium OTC | 9,693,978 |
| Lupin Ltd. v. Horizon Therapeutics, LLC, IPR2018-00459 (PTAB) | Jan. 12, 2018 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,561,197 |
| Catalent Pharma Solutions, Inc. v. Patheon Softgels Inc., IPR2018-00421 (PTAB) | Jan. 14, 2018 | N/A | Naproxen Sodium OTC | 9,693,978 |
| Catalent Pharma Solutions, Inc. v. Patheon Softgels Inc., IPR2018-00422 (PTAB) | Jan. 14, 2018 | N/A | Naproxen Sodium OTC | 9,693,979 |
| Merck Sharp & Dohme Corp. v. MSN Labs. Private Ltd., 18-0675 (D.N.J.) | Jan. 16, 2018 | Hon. Peter G. Sheridan | Emend® (fosaprepitant dimeglumine for injection) | 5,691,336 |
| Takeda Pharms. U.S.A., Inc. v. Dr. Reddy’s Labs., Ltd., 18-0101 (D. Del.) | Jan. 17, 2018 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) | 7,906,519 7,935,731 8,093,298 7,964,648 8,093,297 7,619,004 7,601,758 7,820,681 7,915,269 7,964,647 7,981,938 8,093,296 8,097,655 8,415,395 8,415,396 8,440,721 8,440,722 |
| Janssen Pharms., Inc. v. Teva Pharms. USA, Inc., 18-0734 (D.N.J.) | Jan. 17, 2018 | Hon. John Michael Vazquez | Sustenna® (paliperidone palmitate extended-release injectable suspension) | 9,439,906 |
| West-ward Pharms. Int’l Ltd. v. Novartis Pharms. Corp., IPR2018-00507 (PTAB) | Jan. 17, 2018 | N/A | Afinitor® (everolimus tablets) | 8,410,131 |
| Adverio Pharma GMBH v. MSN Labs. Private Ltd., 18-0111 (D. Del.) | Jan. 19, 2018 | Hon. Leonard P. Stark | Adempas® (riociguat tablets) | 7,173,037 |
| Adverio Pharma GMBH v. Teva Pharms USA, Inc., 18-0112 (D. Del.) | Jan. 19, 2018 | Hon. Leonard P. Stark | Adempas® (riociguat tablets) | 7,173,037 |
| H. Lundbeck A/S v. Alembic Pharms. Ltd., 18-0113 (D. Del.) | Jan. 19, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. MSN Private Labs. Ltd., 18-0114 (D. Del.) | Jan. 19, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| Bristol-Myers Squibb Co. v. Dr. Reddy’s Labs., Ltd., 18-0115 (D. Del.) | Jan. 19, 2018 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 |
| Teva Pharms. Int’l GMBH v. Slayback Pharma Ltd. Liability Co., 18-0117 (D. Del.) | Jan. 19, 2018 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) | 9,572,887 |
| Allergan Sales, LLC v. Aurobindo Pharma USA, Inc., 18-0118 (D. Del.) | Jan. 19, 2018 | Hon. Gregory M. Sleet | Bystolic® (nebivolol HCl tablets) | 6,545,040 |
| Biogen MA Inc. v. Caribe Holdings (Cayman) Co. Ltd., 18-0121 (D. Del.) | Jan. 19, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Onyx Therapeutics, Inc. v. Apotex Inc., 18-0134 (D. Del.) | Jan. 24, 2018 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042 7,232,818 7,491,704 7,737,112 8,129,346 8,207,125 8,207,126 8,207,127 8,207,297 |
| Aurobindo Pharma USA Inc. v. Andrx Corp., IPR2018-00530 (PTAB) | Jan. 24, 2018 | N/A | Fortamet® (metformin HCl extended-release tablets) Actoplus® MET XR (metformin HCl / pioglitazone HCl extended-release tablets) |
6,790,459 |
| H. Lundbeck A/S v. Cipla Ltd., 18-0147 (D. Del.) | Jan. 25, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Prinston Pharm. Inc., 18-0148 (D. Del.) | Jan. 25, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Torrent Pharms. Ltd., 18-0149 (D. Del.) | Jan. 25, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Zydus Pharms. (USA) Inc., 18-0150 (D. Del.) | Jan. 25, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884 8,476,279 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Zydus Pharms. (USA) Inc., 18-1097 (D.N.J.) | Jan. 26, 2018 | Hon. Freda L. Wolfson | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884 8,476,279 8,722,684 8,969,355 9,227,946 |
| Forest Labs. Holdings, Ltd. v. Sandoz Inc., 18-0171 (D. Del.) | Jan. 30, 2018 | Hon. Richard G. Andrews | Linzess® (linaclotide capsules) | 9,708,371 |
| H. Lundbeck A/S v. Amneal Pharms. LLC, 18-0175 (D. Del.) | Jan. 30, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884 8,476,279 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Hetero USA Inc., 18-0176 (D. Del.) | Jan. 30, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 9,861,630 |
| H. Lundbeck A/S v. Sandoz Inc., 18-0177 (D. Del.) | Jan. 30, 2018 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| H. Lundbeck A/S v. Sandoz Inc., 18-1394 (D.N.J.) | Jan. 31, 2018 | Hon. Freda L. Wolfson | Trintellix® (vortioxetine hydrobromide tablets) | 8,722,684 8,969,355 9,227,946 |
| Actelion Pharms. Ltd. v. Zydus Pharms. (USA) Inc., 18-1397 (D.N.J.) | Jan. 31, 2018 | Hon. Freda L. Wolfson | Opsumit® (macitentan tablets) | 7,094,781 |
| Pfizer Inc. v. Ajanta Pharma Ltd., 18-0188 (D. Del.) | Feb. 1, 2018 | Hon. Richard G. Andrews | Viagra® (sildenafil citrate tablets) | 6,469,012 |
| Takeda Pharms. U.S.A., Inc. v. Alkem Labs. Ltd., 18-0189 (D. Del.) | Feb. 1, 2018 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) | 7,906,519 7,935,731 8,093,298 7,964,648 8,093,297 7,619,004 7,601,758 7,820,681 7,915,269 7,964,647 7,981,938 8,093,296 8,097,655 8,415,395 8,415,396 8,440,721 8,440,722 |
| Hospira, Inc. v. Gland Pharma Ltd., 18-0190 (D. Del.) | Feb. 1, 2018 | Hon. Richard G. Andrews | Precedex® (dexmedetomidine HCl for injection) | 8,455,527 8,648,106 9,320,712 9,616,049 |
| Hospira, Inc. v. Jiangsu Hengrui Medicine Co., Ltd., 18-0191 (D. Del.) | Feb. 1, 2018 | Hon. Richard G. Andrews | Precedex® (dexmedetomidine HCl for injection) | 8,455,527 8,648,106 9,320,712 9,616,049 |
| Pharmacyclics LLC v. Fresenius Kabi USA, LLC, 18-0192 (D. Del.) | Feb. 1, 2018 | Hon. Gregory M. Sleet | Imbruvica® (ibrutinib tablets) | 8,008,309 7,514,444 8,697,711 8,735,403 8,957,079 9,181,257 8,754,091 8,497,277 8,952,015 8,476,284 8,754,090 9,296,753 9,725,455 9,540,382 9,713,617 |
| Merck Sharp & Dohme Corp. v. Fresenius Kabi USA, LLC, 18-0196 (D. Del.) | Feb. 2, 2018 | Hon. Gregory M. Sleet | Noxafil® (posaconazole for injection) | 9,023,790 9,358,297 |
| Forest Labs. Holdings, Ltd. v. Teva Pharms. USA, Inc., 18-0198 (D. Del.) | Feb. 2, 2018 | Hon. Richard G. Andrews | Linzess® (linaclotide capsules) | 7,304,036 7,371,727 7,704,947 7,745,409 8,080,526 8,110,553 8,933,030 9,708,371 |
| Purdue Pharma L.P. v. Collegium NF, LLC, 18-0026 (D. Del.) | Feb. 7, 2018 | Hon. Gregory M. Sleet | Nucynta® IR (tapentadol tablets) Nucynta® ER (tapentadol extended-release tablets) |
9,861,583 9,867,784 9,872,836 |
| Indivior Inc. v. Dr. Reddy’s Labs. S.A., 18-1775 (D.N.J.) | Feb. 7, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,855,221 |
| Indivior Inc. v. Teva Pharms. USA, Inc., 18-1777 (D.N.J.) | Feb. 7, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,855,221 |
| Indivior Inc. v. Par Pharm., Inc., 18-1780 (D.N.J.) | Feb. 7, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,855,221 |
| Indivior Inc. v. Actavis Labs. UT Inc, 18-0124 (D. Utah) | Feb. 7, 2018 | Hon. Dustin B. Pead | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,855,221 |
| Pharmacyclics LLC v. Shilpa Medicare Ltd., 18-0237 (D. Del.) | Feb. 9, 2018 | Hon. Gregory M. Sleet | Imbruvica® (ibrutinib tablets) | 9,296,753 9,725,455 8,999,999 9,801,881 9,801,883 |
| Pharmacyclics LLC v. Cipla Ltd., 18-0247 (D. Del.) | Feb. 12, 2018 | Hon. Gregory M. Sleet | Imbruvica® (ibrutinib tablets) | 9,296,753 9,725,455 9,540,382 9,713,617 8,754,090 9,125,889 |
| Takeda Pharm. Co. Ltd. v. Zydus Pharms (USA) Inc., 18-1994 (D.N.J.) | Feb. 12, 2018 | Hon. Freda L. Wolfson | Prevacid® SoluTab™ (lansoprazole delayed-release orally-disintegrating tablets) | 6,328,994 7,431,942 7,875,292 7,399,485 |
| Amneal Pharms. LLC v. Allergan, Inc., IPR2018-00608 (PTAB) | Feb. 12, 2018 | N/A | Aczone® (dapsone topical gel) | 9,161,926 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Amneal Pharms. LLC, 18-0256 (D. Del.) | Feb. 13, 2018 | Hon. Richard G. Andrews | Latuda® (lurasidone HCl tablets) | 9,815,827 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharms. Ltd., 18-2065 (D.N.J.) | Feb. 13, 2018 | Hon. Stanley R. Chesler | Latuda® (lurasidone HCl tablets) | 9,815,827 |
| Bayer Healthcare Pharms. Inc. v. Perrigo UK Finco Ltd. Partnership, 18-0261 (D. Del.) | Feb. 15, 2018 | Vacant Judgeship (2017) | Finacea® (azelaic acid foam) | 7,700,076 8,435,498 8,722,021 8,900,554 9,211,259 9,265,725 |
| Onyx Therapeutics, Inc. v. Berckenridge Pharm., Inc., 18-0262 (D. Del.) | Feb. 15, 2018 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042 7,232,818 7,491,704 7,737,112 8,129,346 8,207,125 8,207,126 8,207,127 8,207,297 |
| Sun Pharma Global FZE v. Lupin Ltd., 18-2213 (D.N.J.) | Feb. 15, 2018 | Hon. Freda L. Wolfson | BromSite® (bromfenac ophthalmic solution) | 8,778,999 |
| Pharmacyclics LLC v. Zydus Worldwide DMCC., 18-0275 (D. Del.) | Feb. 16, 2018 | Hon. Gregory M. Sleet | Imbruvica® (ibrutinib tablets) | 8,008,309 7,514,444 8,697,711 8,735,403 8,957,079 9,181,257 8,754,091 8,497,277 8,952,015 8,476,284 8,754,090 9,296,753 9,725,455 8,999,999 9,125,889 9,801,881 9,801,883 9,814,721 9,795,604 9,713,617 |
| Osmotica Pharm. US LLC v. Adamas Pharms., Inc., 18-0278 (D. Del.) | Feb. 16, 2018 | Hon. Gregory M. Sleet | Osmolex ER® (amantadine HCl tablets) | 8,389,578 8,741,343 8,796,337 8,889,740 8,895,614 8,895,615 8,895,616 8,895,617 8,895,618 8,987,333 9,072,697 |
| Bial – Portela & Ca., S.A. v. Torrent Pharms. Ltd., 18-0279 (D. Del.) | Feb. 16, 2018 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| Pfizer Inc. v. Appco Pharma Ltd., 18-2272 (D.N.J.) | Feb. 16, 2017 | Hon. Brian R. Martinotti | Viagra® (sildenafil citrate tablets) | 6,469,012 |
| BTG Int’l Ltd. v. MSN Pharms. Inc., 18-2372 (D.N.J.) | Feb. 20, 2018 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Collegium Pharm., Inc. v. Teva Pharms USA, Inc., 18-300 (D. Del.) | Feb. 22, 2018 | Hon. Leonard P. Stark | Xtampza® ER (oxycodone extended-release capsules) | 7,399,488 7,771,707 8,449,909 8,557,291 8,758,813 8,840,928 9,044,398 9,248,195 9,592,200 9,682,075 9,737,530 9,763,883 |
| Baxter Healthcare Corp. v. Hospira, Inc., 18-0303 (D. Del.) | Feb. 22, 2018 | Hon. Richard G. Andrews | Precedex® (dexmedetomidine HCl for injection) | 6,716,867 8,242,158 8,338,470 8,455,527 |
| Bial – Portela & Ca., S.A. v. Alkem Labs. Ltd., 18-0304 (D. Del.) | Feb. 22, 2018 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| Bial – Portela & Ca., S.A. v. Lupin Ltd., 18-0312 (D. Del.) | Feb. 23, 2018 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Aurobindo Pharma Ltd., 18-2620 (D.N.J.) | Feb. 23, 2018 | Hon. Stanley R. Chesler | Latuda® (lurasidone HCl tablets) | 9,815,827 |
| Apotex Inc. v. Celgene Corp., IPR2018-00685 (PTAB) | Feb. 23, 2018 | N/A | Revlimid® (lenalidomide capsules) | 8,741,929 |
| Kashiv Pharma, LLC v. Purdue Pharma L.P., IPR2018-00625 (PTAB) | Feb. 27, 2018 | N/A | OxyContin® (oxycodone HCl extended-release tablets) | 9,492,392 |
| Kashiv Pharma, LLC v. Purdue Pharma L.P., IPR2018-00717 (PTAB) | Feb. 28, 2018 | N/A | OxyContin® (oxycodone HCl extended-release tablets) | 9,492,393 |
| Bial – Portela & Ca., S.A. v. Jubilant Life Sciences Ltd., 18-0336 (D. Del.) | Mar. 1, 2018 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| Biogen Int’l GMBH v. MSN Labs. Private Ltd., 18-0337 (D. Del.) | Mar. 1, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 |
| Fresenius Kabi USA, LLC v. BioQ Pharma Inc., 18-3032 (D.N.J.) | Mar. 1, 2018 | Hon. Susan D. Wigenton | Diprivan® (propofol for injection) | 8,476,010 |
| Fresenius Kabi USA, LLC v. BioQ Pharma Inc., 18-1408 (N.D. Cal.) | Mar. 2, 2018 | Hon. Jeffrey S. White | Diprivan® (propofol for injection) | 8,476,010 |
| Bial – Portela & Ca., S.A. v. Dr. Reddy’s Labs., Ltd., 18-0341 (D. Del.) | Mar. 2, 2018 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| Bial – Portela & Ca., S.A. v Hetero Labs Ltd., 18-0342 (D. Del.) | Mar. 2, 2018 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| Bial – Portela & Ca., S.A. v. Dr. Reddy’s Labs., Ltd., 18-3098 (D.N.J.) | Mar. 2, 2018 | Hon. Freda L. Wolfson | Aptiom® (eslicarbazepine acetate tablets) | 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| Biogen Int’l GMBH v. Impax Labs., Inc., 18-0350 (D. Del.) | Mar. 5, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 |
| Boehringer Ingelheim Pharms., Inc. v. Fresenius Kabi USA, LLC, 18-3244 (D.N.J.) | Mar. 7, 2018 | Hon. Michael A. Shipp | Gilotrif® (afatinib tablets) | RE43,431 8,426,586 |
| Sumitomo Dainippon Pharma Co., Ltd. v. InvaGen Pharms., Inc., 18-1444 (E.D.N.Y.) | Mar. 8, 2018 | Hon. Pamela K. Chen | Latuda® (lurasidone HCl tablets) | 9,815,827 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Par Pharm., Inc., 18-2107 (S.D.N.Y.) | Mar. 8, 2018 | Hon. Ronnie Abrams | Latuda® (lurasidone HCl tablets) | 9,815,827 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Accord Healthcare, Inc., 18-0185 (M.D.N.C.) | Mar. 8, 2018 | Hon. Loretta C. Biggs | Latuda® (lurasidone HCl tablets) | 9,815,827 |
| Sumitomo Dainippon Pharma Co., Ltd. v. First Time US Generics, LLC, 18-0369 (D. Del.) | Mar. 8, 2018 | Hon. Richard G. Andrews | Latuda® (lurasidone HCl tablets) | 9,815,827 |
| Pfizer Inc. v. Prinston Pharm. Inc., 18-0380 (D. Del.) | Mar. 9, 2018 | Hon. Leonard P. Stark | Xeljanz® (tofacitinib tablets) | RE41,783 |
| Bial – Portela & Ca., S.A. v. Apotex Inc., 18-0382 (D. Del.) | Mar. 9, 2018 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA, 18-0390 (D. Del.) | Mar. 12, 2018 | Hon. Leonard P. Stark | Velphoro® (sucroferric oxyhydroxide chewable tablets) | 6,174,442 9,561,251 |
| Collegium Pharm., Inc. v. Purdue Pharma L.P., PGR2018-00048 (PTAB) | Mar. 13, 2018 | N/A | OxyContin® (oxycodone HCl extended-release tablets) | 9,693,961 |
| Leo Pharma A/S v. Perrigo UK Finco Ltd., 18-0401 (D. Del.) | Mar. 14, 2018 | Hon. Joseph F. Bataillon | Picato® (ingenol Mebutate gel) | 8,278,292 9,820,959 9,833,428 9,833,429 |
| Leo Pharma A/S v. Actavis Labs. UT, Inc., 18-0402 (D. Del.) | Mar. 14, 2018 | Hon. Joseph F. Bataillon | Picato® (ingenol Mebutate gel) | 8,278,292 9,820,959 9,833,428 9,833,429 |
| Purdue Pharma L.P. v. Intellipharmaceutics Int’l Inc., 18-0404 (D. Del.) | Mar. 14, 2018 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) | 9,060,976 9,073,933 9,522,919 9,492,389 9,492,391 9,775,808 9,763,886 9,763,933 8,309,060 9,675,610 |
| Gilead Sciences, Inc. v. Natco Pharma Ltd., 18-3592 (D.N.J.) | Mar. 14, 2018 | Hon. Peter G. Sheridan | Sovaldi® (sofosbuvir tablets) | 8,618,076 9,284,342 7,429,572 8,415,322 9,206,217 9,340,568 |
| Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc., 18-3632 (D.N.J.) | Mar. 15, 2018 | Hon. Susan D. Wigenton | Korlym® (mifepristone tablets) | 8,921,348 9,829,495 |
| Gilead Sciences, Inc. v. Natco Pharma Ltd., 18-0411 (D. Del.) | Mar. 16, 2018 | Hon. Leonard P. Stark | Sovaldi® (sofosbuvir tablets) | 8,618,076 9,284,342 7,429,572 8,415,322 9,206,217 9,340,568 |
| Insys Therapeutics, Inc. v. Teva Pharms. USA, Inc., 18-0414 (D. Del.) | Mar. 16, 2018 | Hon. Gregory M. Sleet | Subsys® (fentanyl sublingual spray) | 8,486,972 8,486,973 8,835,459 8,835,460 9,241,935 9,289,387 9,642,797 9,642,844 |
| Merck Sharp & Dohme Corp. v. Mylan Labs. Ltd., 18-0450 (D. Del.) | Mar. 23, 2018 | Hon. Gregory M. Sleet | Noxafil® (posaconazole for injection) | 9,023,790 9,358,297 |
| Taro Pharms U.S.A., Inc. v. Lupin Ltd., 18-4225 (D.N.J.) | Mar. 23, 2018 | Hon. John Michael Vazquez | Topicort® (desoximetasone topical spray) | 8,277,780 8,715,624 |
| Delcor Asset Corp. v. Glenmark Pharms. Ltd., 18-0460 (D. Del.) | Mar. 26, 2018 | Vacant Judgeship (2017) | Olux-E® (clobetasol propionate aerosol foam) | 6,730,288 |
| Gilead Sciences, Inc. v. Teva Pharms. USA, Inc., 18-4273 (D.N.J.) | Mar. 26, 2018 | Hon. Peter G. Sheridan | Sovaldi® (sofosbuvir tablets) | 7,964,580 8,334,270 8,580,765 9,085,573 7,429,572 8,415,322 8,633,309 9,284,342 8,618,076 9,549,941 8,889,159 8,629,263 8,735,569 9,637,512 8,642,756 9,206,217 9,340,568 |
| Takeda Pharms. U.S.A., Inc. v. Zydus Pharms. (USA) Inc., 18-0464 (D. Del.) | Mar. 27, 2018 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) | 7,906,519 7,935,731 8,093,298 7,964,648 8,093,297 7,619,004 7,601,758 7,820,681 7,915,269 7,964,647 7,981,938 8,093,296 8,097,655 8,415,395 8,415,396 8,440,721 8,440,722 |
| Gilead Sciences, Inc. v. Teva Pharms. USA, Inc., 18-0466 (D. Del.) | Mar. 27, 2018 | Unassigned Judge | Sovaldi® (sofosbuvir tablets) | 7,964,580 8,334,270 8,580,765 9,085,573 7,429,572 8,415,322 8,633,309 9,284,342 8,618,076 9,549,941 8,889,159 8,629,263 8,735,569 9,637,512 8,642,756 9,206,217 9,340,568 |
| Bracco Diagnostics Inc. v. Jubilant Draximage Inc., 18-4422 (D.N.J.) | Mar. 27, 2018 | Hon. Michael A. Shipp | CardioGen-82 (rubidium 82 generator) Ruby-Fill® (strontium-rubidium radioisotope infusion system) |
9,814,826 9,750,869 9,750,870 9,299,467 9,299,468 |
| Takeda Pharms. U.S.A., Inc. v. Zydus Pharms (USA) Inc., 18-4591 (D.N.J.) | Mar. 28, 2018 | Hon. Michael A. Shipp | Colcrys® (colchicine tablets) | 7,906,519 7,935,731 8,093,298 7,964,648 8,093,297 7,619,004 7,601,758 7,820,681 7,915,269 7,964,647 7,981,938 8,093,296 8,097,655 8,415,395 8,415,396 8,440,721 8,440,722 |
| Forest Labs. Holdings, Ltd. v. Mylan Pharms. Inc., 18-0482 (D. Del.) | Mar. 29, 2018 | Unassigned Judge | Linzess® (linaclotide capsules) | 7,304,036 7,371,727 7,704,947 7,745,409 8,080,526 8,110,553 8,933,030 |
| Merck Sharp & Dohme Corp. v. Mylan Labs. Ltd., 18-1334 (E.D. Pa.) | Mar. 29, 2018 | Hon. Gene E.K. Pratter | Noxafil® (posaconazole for injection) | 9,023,790 9,358,297 |
GENERICally Speaking Spring 2018
Related Professionals
Christopher A. Pinahs
Partner
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.